• LAST PRICE
    5.3636
  • TODAY'S CHANGE (%)
    Trending Up0.0436 (0.8195%)
  • Bid / Lots
    5.3600/ 12
  • Ask / Lots
    5.3700/ 9
  • Open / Previous Close
    5.3000 / 5.3200
  • Day Range
    Low 5.1300
    High 5.3700
  • 52 Week Range
    Low 4.9100
    High 11.9100
  • Volume
    456,448
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 5.32
TimeVolumeEDIT
09:32 ET223035.285
09:34 ET23635.285
09:36 ET21155.24
09:38 ET8925.24
09:39 ET18045.23
09:41 ET9005.25
09:43 ET32425.2595
09:45 ET25855.2216
09:48 ET13005.23
09:50 ET35035.23
09:52 ET4885.22
09:54 ET16175.2
09:56 ET13005.18
09:57 ET51195.165
09:59 ET30015.17
10:01 ET177815.17
10:03 ET21505.1973
10:06 ET6505.205
10:08 ET31255.2
10:10 ET16325.19
10:12 ET24365.18
10:14 ET7005.175
10:15 ET11005.16
10:17 ET43355.18
10:19 ET159005.175
10:21 ET34235.14
10:24 ET30105.15
10:26 ET41115.163
10:28 ET41585.16
10:30 ET17005.1573
10:32 ET29355.175
10:33 ET13655.185
10:35 ET90285.185
10:37 ET4975.18
10:39 ET58715.205
10:42 ET138075.22
10:44 ET10065.195
10:46 ET12445.2
10:48 ET7045.205
10:50 ET13005.205
10:51 ET9005.215
10:53 ET7005.21
10:55 ET22835.21
10:57 ET44265.207
11:00 ET3005.2048
11:02 ET16265.205
11:04 ET26885.205
11:06 ET1005.21
11:08 ET3005.195
11:09 ET30645.1809
11:13 ET11005.185
11:15 ET8065.195
11:18 ET15415.2
11:20 ET2005.205
11:22 ET45995.215
11:24 ET1005.215
11:26 ET2005.215
11:27 ET42525.2277
11:29 ET7005.215
11:31 ET15065.215
11:33 ET58005.215
11:36 ET49805.2
11:38 ET26665.205
11:40 ET80555.21
11:42 ET1005.21
11:44 ET9005.21
11:45 ET3055.21
11:47 ET7005.205
11:49 ET1005.21
11:51 ET8005.215
11:54 ET6005.215
11:56 ET100925.22
11:58 ET1005.22
12:00 ET21905.235
12:02 ET47775.25
12:03 ET4505.244
12:05 ET11005.25
12:07 ET15995.255
12:09 ET101985.245
12:12 ET2005.245
12:14 ET23055.255
12:16 ET17005.255
12:18 ET29255.245
12:20 ET14105.245
12:21 ET7905.2408
12:23 ET44755.245
12:25 ET12125.247
12:27 ET3005.245
12:30 ET1005.245
12:32 ET15005.25
12:34 ET17005.25
12:36 ET12985.26
12:38 ET3975.265
12:39 ET1005.26
12:41 ET25905.275
12:43 ET23845.28
12:45 ET12005.285
12:48 ET5755.285
12:50 ET17805.28
12:52 ET36895.29
12:54 ET4005.295
12:56 ET83105.305
12:57 ET23235.285
12:59 ET1005.28
01:01 ET1005.285
01:03 ET127765.3206
01:06 ET26005.33
01:08 ET3005.32
01:10 ET27965.3212
01:12 ET18025.34
01:14 ET6005.3326
01:15 ET1005.335
01:17 ET52875.34
01:19 ET4525.335
01:21 ET13005.3309
01:24 ET124425.32
01:26 ET1005.325
01:28 ET37395.345
01:30 ET23355.34
01:32 ET12005.34
01:33 ET101935.335
01:35 ET33535.34
01:37 ET32465.345
01:39 ET9005.34
01:42 ET11005.34
01:44 ET56405.365
01:46 ET53045.365
01:48 ET5005.365
01:50 ET8565.3636
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEDIT
Editas Medicine Inc
435.9M
-2.6x
---
United StatesURGN
Urogen Pharma Ltd
477.3M
-3.8x
---
United StatesFATE
Fate Therapeutics Inc
418.9M
-2.0x
---
United StatesYMAB
Y-mAbs Therapeutics Inc
525.7M
-24.1x
---
United StatesALEC
Alector Inc
420.2M
-3.1x
---
United StatesADCT
ADC Therapeutics SA
329.0M
-1.2x
---
As of 2024-06-11

Company Information

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Contact Information

Headquarters
11 Hurley StCAMBRIDGE, MA, United States 02141-2110
Phone
617-401-9000
Fax
302-655-5049

Executives

Independent Chairman of the Board
Emma Reeve
President, Chief Executive Officer, Director
Gilmore O'Neill
Chief Financial Officer, Executive Vice President
Erick Lucera
Executive Vice President, Chief Scientific Officer
Linda Burkly
Senior Vice President, Chief Medical Officer
Baisong Mei

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$435.9M
Revenue (TTM)
$69.4M
Shares Outstanding
82.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.02
EPS
$-2.10
Book Value
$4.27
P/E Ratio
-2.6x
Price/Sales (TTM)
6.3
Price/Cash Flow (TTM)
---
Operating Margin
-266.85%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.